Bücher zum Thema „Enzyme activation“

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Enzyme activation.

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Bücher für die Forschung zum Thema "Enzyme activation" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Bücher für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Ottaway, J. H. Regulation of enzyme activity. Oxford: IRL Press, 1988.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

H, Stenmark, Hrsg. Phosphoinositides in subcellular targeting and enzyme activation. Berlin: Springer, 2004.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Stein, Ross L. Kinetics of enzyme action: Essential principles for drug hunters. Hoboken, N.J: John Wiley, 2011.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Stenmark, Harald, Hrsg. Phosphoinositides in Subcellular Targeting and Enzyme Activation. Berlin, Heidelberg: Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-642-18805-3.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Krupi͡anko, V. I. Vektornyĭ metod predstavlenii͡a fermentativnykh reakt͡siĭ. Moskva: "Nauka", 1990.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Alan, Wiseman, Hrsg. Enzyme induction, mutagen activation, and carcinogen testing in yeast. Chichester, West Sussex, England: E. Horwood, 1987.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

H, Schmid-Schönbein, Wurzinger L. J, Zimmermann R. E und Commission of the European Communities. Committee on Medical and Public Health Research., Hrsg. Enzyme activation in blood-perfused artificial organs: Proceedings of an interdisciplinary meeting. Boston: Nijhoff, 1985.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Mordechai, Liscovitch, Hrsg. Signal-activated phospholipases. Austin: R.G. Landes Co., 1994.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Akira, Arimura, Saʻīd Sāmī und International Symposium on VIP, PACAP, and Related Peptides (2nd : 1995 : New Orleans, La.), Hrsg. VIP, PACAP, and related peptides: Second international symposium. New York: New York Academy of Sciences, 1996.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Light, P. E. An investigation into factors controlling activation of the enzyme protein Kinase C in the regulation of neurotransmitter release at the frog neuromuscular junction. Birmingham: University of Birmingham, 1990.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
11

Chen, Chang-Hwei. Activation and Detoxification Enzymes. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-1049-2.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
12

1923-, Lorand Laszlo, und Mann Kenneth G, Hrsg. Proteolytic enzymes in coagulation, fibrinolysis, and complement activation. San Diego: Academic Press, 1993.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
13

Rossomando, Edward F. HPLC in enzymatic analysis. 2. Aufl. New York: Wiley, 1998.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
14

M, Cunningham Fiona, Hrsg. Lipid mediators. London: Academic Press, 1994.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
15

C, Murphy Robert, und Fitzpatrick Frank A, Hrsg. Arachidonate related lipid mediators. San Diego: Academic Press, 1990.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
16

L, Schramm Vern, und Purich Daniel L, Hrsg. Enzyme kinetics and mechanism. 1999.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
17

Enzyme kinetics and mechanism. San Diego: Academic Press, 2002.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
18

Stein, Ross L. Kinetics of Enzyme Action. Wiley & Sons, Incorporated, John, 2011.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
19

Stenmark, Harald. Phosphoinositides in Subcellular Targeting and Enzyme Activation. Springer London, Limited, 2012.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
20

Stein, Ross L. Kinetics of Enzyme Action: Essential Principles for Drug Hunters. Wiley & Sons, Incorporated, John, 2011.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
21

Stein, Ross L. Kinetics of Enzyme Action: Essential Principles for Drug Hunters. Wiley & Sons, Incorporated, John, 2011.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
22

Stein, Ross L. Kinetics of Enzyme Action: Essential Principles for Drug Hunters. Wiley & Sons, Incorporated, John, 2011.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
23

Stenmark, Harald. Phosphoinositides in Subcellular Targeting and Enzyme Activation. Springer, 2012.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
24

Stenmark, Harald. Phosphoinositides in Subcellular Targeting and Enzyme Activation. Springer, 2003.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
25

Engel, P. C. Enzymology LabFax (Labfax Series). Academic Press, 1996.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
26

Baici, Antonio. Kinetics of Enzyme-Modifier Interactions: Selected Topics in the Theory and Diagnosis of Inhibition and Activation Mechanisms. Baici Antonio, 2015.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
27

Baici, Antonio. Kinetics of Enzyme-Modifier Interactions: Selected Topics in the Theory and Diagnosis of Inhibition and Activation Mechanisms. Springer, 2016.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
28

Baici, Antonio. Kinetics of Enzyme-Modifier Interactions: Selected Topics in the Theory and Diagnosis of Inhibition and Activation Mechanisms. Springer London, Limited, 2015.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
29

Activation And Detoxification Enzymes Functions And Implications. Springer, 2011.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
30

Cooper, A. The Enzyme Catalysis Process:Energetics, Mechanism and Dynamics. Springer, 1989.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
31

Cascorbi, Ingolf. Polymorphic cytochrome P450 2D6 as the responsible enzyme of activation. Herausgegeben von Paul Farquhar-Smith, Pierre Beaulieu und Sian Jagger. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198834359.003.0079.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Annotation:
The landmark paper discussed in this chapter is ‘Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)’, published by Dayer et al. in 1988. Codeine is an old but frequently prescribed drug used for the treatment of mild-to-moderate pain. However, its use is nowadays restricted after observations of partly fatal respiratory repression in children. Codeine itself exhibits no analgesic effect, but is partly activated by O-demethylation to morphine by cytochrome P450 2D6 (CYP2D6). The identification of the polymorphic CYP2D6 as the enzyme responsible for activation was achieved by Dayer et al. in 1998 and was an important milestone contributing to the widely observed inter-individual differences of drug action and side effects of codeine. Translating the pharmacogenetics of codeine into clinical practice is currently underway in clinical trials, to identify ineffective analgesics and, in particular, avoid severe adverse events.
32

Soda, Kenji, und Toshio Fukui. Molecular Aspects of Enzyme Catalysis. Wiley & Sons, Incorporated, John, 2008.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
33

Molecular aspects of enzyme catalysis. Tokyo: Kodansha, 1994.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
34

Fukui, Tukui, und Kenji Soda. Molecular Aspects of Enzyme Catalysis. Vch Pub, 1994.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
35

Soda, Kenji, und Toshio Fukui. Molecular Aspects of Enzyme Catalysis. Wiley & Sons, Limited, John, 2007.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
36

Lyle, Stephen. The sulfate-activation pathway: A bifunctional enzyme which utilizes intermediate channeling. 1993.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
37

Clarke, Andrew. Temperature and reaction rate. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780199551668.003.0007.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Annotation:
All other things being equal, physiological reaction rate increases roughly exponentially with temperature. Organisms that have adapted over evolutionary time to live at different temperatures can have enzyme variants that exhibit similar kinetics at the temperatures to which they have adapted to operate. Within species whose distribution covers a range of temperatures, there may be differential expression of enzyme variants with different kinetics across the distribution. Enzymes adapted to different optimum temperatures differ in their amino acid sequence and thermal stability. The Gibbs energy of activation tends to be slightly lower in enzyme variants adapted to lower temperatures, but the big change is a decrease in the enthalpy of activation, with a corresponding change in the entropy of activation, both associated with a more open, flexible structure. Despite evolutionary adjustments to individual enzymes involved in intermediary metabolism (ATP regeneration), many whole-organism processes operate faster in tropical ectotherms compared with temperate or polar ectotherms. Examples include locomotion (muscle power output), ATP regeneration (mitochondrial function), nervous conduction and growth.
38

Brown, Stephanie Leanne. The biosynthesis of poly (ribitol-phosphate) wall teichoic acids and the roles of individual tailoring modifications. 2011.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
39

Smerage, Jeffrey. Activated Transcription of the Glycolytic Enzyme Genes of Saccharomyces Cerevisiae: The Chromatin Structures of TP11 and Mechanisms of RAP1P Mediated Activation. Dissertation Discovery Company, 2018.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
40

Smerage, Jeffrey. Activated Transcription of the Glycolytic Enzyme Genes of Saccharomyces Cerevisiae: The Chromatin Structures of TP11 and Mechanisms of RAP1P Mediated Activation. Creative Media Partners, LLC, 2018.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
41

Chen, Chang-Hwei. Activation and Detoxification Enzymes: Functions and Implications. Springer, 2014.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
42

Chen, Chang-Hwei. Activation and Detoxification Enzymes: Functions and Implications. Springer, 2011.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
43

Deegan, Patrick. Porphyria. Herausgegeben von Patrick Davey und David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0179.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Annotation:
This chapter discusses six diseases caused by inborn errors of metabolism affecting the biosynthesis of haem. Haem is a tetracyclic metal-binding compound involved in oxygen transport (in haemoglobin and myoglobin) and redox reactions (e.g. in the cytochrome P450 system). Each of these conditions is caused by a single gene defect in one of the enzymes involved in the biosynthesis of haem. Inheritance is usually autosomal dominant with incomplete penetrance. The enzyme defect results in disease, not as a result of deficiency of the reaction product, but as a result of accumulation of precursors. Early, soluble precursors, 5-aminolaevulinic acid, and porphobilinogen (not porphyrins as such) are neurotoxic and, when present in great excess, as occurs when flux through the haem synthetic pathway is increased in response to particular medications or hormones, lead to acute neurovisceral crises. Later cyclical precursors (porphyrins) in the pathway are also water soluble and excreted in urine, but are susceptible to activation by electromagnetic radiation in the visible spectrum and are converted to free-radical metabolites that cause pain, inflammation, and tissue damage in the skin. The final haem precursors (also porphyrins) are hydrophobic and excreted in the bile and faeces and are also activated by light to toxic metabolites.
44

O’Neal, M. Angela. Pain in the Back. Herausgegeben von Angela O’Neal. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190609917.003.0006.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Annotation:
This case explores how bone health can be affected by antiepileptic drugs (AEDs), and why this is an important issue in women with epilepsy (WWE). AEDs affect bone health through activation of the cytochrome P450 system in the liver, leading to increased metabolism of vitamin D. The enzyme-inducing AEDs include phenytoin, carbamazepine, phenobarbital, and primidone. Risk factors for osteoporosis include female gender, low body mass, inadequate vitamin D intake, and smoking. The specific AEDs used and the length of treatment confer additional risks. Furthermore, in WWE, risks are magnified related to falls, either from seizures or related to medication toxicity. Screening with bone density and measures to promote bone health are extremely important in these at-risk women.
45

Hester, Charles K. Mitogen-Activated Protein Kinases: Activation, Functions and Regulation. Nova Science Publishers, Incorporated, 2019.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
46

Rossomando, Edward F. HPLC in Enzymatic Analysis. Wiley & Sons, Incorporated, John, 2009.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
47

Frenkel, Joost, und Hans R. Waterham. Mevalonate Kinase Deficiency. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199972135.003.0039.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Annotation:
Mevalonate kinase deficiency (MKD) is an autosomal recessive inborn error of isoprenoid biosynthesis, a pathway yielding sterols and nonsterol isoprenoids.In patients, the enzyme activity of mevalonate kinase is severely reduced due to mutations in the encoding gene, MVK. The substrate, mevalonate, accumulates and is elevated in blood and urine. Shortage of certain downstream products of the pathway, nonsterol isoprenoids, leads to dysregulation of the innate immune system, activation of inflammasomes, and interleukin (IL)-1 mediated inflammation.Symptoms start in early childhood with recurrent attacks of fever, vomiting, diarrhea, headache, sore throat, abdominal pain, arthralgias, painful lymphadenopathy, hepatosplenomegaly, skin rash, and mucosal ulcers. Severely affected patients have additional symptoms, such as intellectual impairment, progressive cerebellar ataxia, and tapetoretinal degeneration. Complications include intestinal obstruction, AA-amyloidosis, hemophagocytosis, and severe infection.Management of MKD is directed at controlling inflammation.
48

(Editor), John N. Abelson, Melvin I. Simon (Editor), Laszlo Lorand (Editor) und Kenneth G. Mann (Editor), Hrsg. Proteolytic Enzymes in Coagulation, Fibrinolysis, and Complement Activation, Part B, Volume 223: Volume 223: Proteolytic Enzymes in Coagulation, Fibrinolysis ... Activation Part B (Methods in Enzymology). Academic Press, 1993.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
49

Rider, Lisa G., und Frederick W. Miller. Outcome assessment in the idiopathic inflammatory myopathies. Herausgegeben von Hector Chinoy und Robert Cooper. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198754121.003.0016.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Annotation:
Due to their rarity, heterogeneity, and multispecialty nature, the myositis syndromes have limited data-driven consensus on appropriate outcome measures. Recently, two international, multispecialty consortia developed new tools and consensus on core set measures of myositis disease activity and damage, as well as response criteria that are now recommended for use as clinical trial endpoints but will also be useful in clinical practice. Magnetic resonance imaging, muscle ultrasound, selected laboratory tests, and immunological biomarkers—including cytokines, chemokines, lymphocyte flow cytometry, and endothelial activation markers—can all be helpful adjuncts to serum muscle enzyme levels in assessing disease activity and damage, but these have not yet been fully validated. Definitions of clinically inactive disease, complete clinical response, and remission have also been proposed but require further validation. These advances should enhance the development of therapies by standardizing our ability to demonstrate their efficacy in treating the idiopathic inflammatory myopathies.
50

Abelson, John N., Laszlo Lorand, Melvin I. Simon und Kenneth G. Mann. Proteolytic Enzymes in Coagulation, Fibrinolysis, and Complement Activation, Part B. Elsevier Science & Technology Books, 1993.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Zur Bibliographie